Patents Assigned to Caprion Pharmaceuticals, Inc.
  • TAT- 001 and methods of assessing and treating cancer
    Publication number: 20070106065
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity.
    Type: Application
    Filed: January 31, 2006
    Publication date: May 10, 2007
    Applicant: Caprion Pharmaceuticals, Inc.
    Inventors: Paul Kearney, Heather Butler, Navdeep Jaitly, Sajani Swamy, Lyes Hamaidi, Marcelo Filgueira, Pierre Thibault, Denis Faubert, Daniel Chelsky, Joel Lanoix, Sylvain Brunet, Kevin Eng, Frank Aguilera, John Tsang, Michael Hu, Joachim Ostermann, Marguerite Boulos
  • Antibodies to a YYX epitope of a mammalian prion protein
    Patent number: 7041807
    Abstract: In general, the invention features antibodies specific for PrPSc and diagnostic, therapeutic, and decontamination uses thereof. The invention also features synthetic peptides useful as immunogens for generating antibodies specific for PrPSc and therapeutic for the treatment of prion diseases.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: May 9, 2006
    Assignee: Caprion Pharmaceuticals, Inc.
    Inventors: Neil R. Cashman, Eustache Paramithiotis, Jacek Slon-Usakiewicz, Ashkan Haghighat, Marc Pinard, Trebor Lawton